Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients

Phase 4

Completed

Conditions: Coronary Artery Disease (CAD)

Interventions: Drug: Clopidogrel
Drug: aspirin 100mg

First Posted Date: 2013-04-12

Last Posted Date: 2016-10-12

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 162

Registration Number: NCT01830491

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Phase 3

Completed

Conditions: Percutaneous Coronary Intervention
Atrial Fibrillation

Interventions: Drug: rivaroxaban 15 mg
Drug: rivaroxaban 2.5 mg
Drug: rivaroxaban 10 mg
Drug: vitamin K antagonist (VKA)
Drug: aspirin (ASA)
Drug: clopidogrel
Drug: prasugrel
Drug: ticagrelor

First Posted Date: 2013-04-12

Last Posted Date: 2017-09-19

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 2124

Registration Number: NCT01830543

Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study

Phase 4

Withdrawn

Conditions: Acute Coronary Syndrome
Coronary Artery Disease

Interventions: Drug: Ticagrelor
Drug: Clopidogrel
Device: Optical Coherence Tomography

First Posted Date: 2013-04-08

Last Posted Date: 2016-12-20

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT01826175

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy

Phase 4

Conditions: Coronary Artery Disease
Myocardial Infarction
Vascular Disease
Angina Pectoris
Cardiovascular Disease
Ischemia
Infarction
Embolism
Thrombosis
Chest Pain

Interventions: Drug: clopidogrel
Drug: Ticagrelor or prasugrel

First Posted Date: 2013-04-04

Last Posted Date: 2016-01-22

Lead Sponsor: Imam Abdulrahman Bin Faisal University

Target Recruit Count: 1500

Registration Number: NCT01823185

Locations: 🇸🇦
Prince Sultan Cardiac center, Al-Hasa, Saudi Arabia
🇸🇦
Saud Al-Babtain Cardiac Center, Dammam, Saudi Arabia
🇸🇦
King Fahd Military Medical Complex, Dammam, Saudi Arabia

and more 1 locations

Pharmacogenomics of Antiplatelet Response - I

Phase 4

Completed

Conditions: Coronary Artery Disease
Platelet Aggregation
Platelet Transcriptome

Interventions: Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2013-03-20

Last Posted Date: 2017-01-09

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 19

Registration Number: NCT01815008

Locations: 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Phase 3

Completed

Conditions: Coronary Artery Disease (CAD)

Interventions: Drug: Ticagrelor
Drug: Acetylsalicylic Acid
Drug: Clopidogrel

First Posted Date: 2013-03-19

Last Posted Date: 2022-03-15

Lead Sponsor: ECRI bv

Target Recruit Count: 15991

Registration Number: NCT01813435

Locations: 🇧🇪
Research centre Aalst, 3201, Aalst, Belgium
🇧🇪
Research centre Genk, 3205, Genk, Belgium
🇦🇹
Research centre Graz, 4305, Graz, Austria

and more 127 locations